In this patient cohort, considerable numbers of the recurrent patients had recurrences later than 9 months.
There were a total of 14 recurrences in six recurrent patients.
Then, the clinical characteristics were compared between asymptomatic patients, no recurrent patients (BI-no recurrence) and recurrent patients (BI-recurrence).
In our study, seven patients with primary disease achieved complete remission (CR) and were alive without recurrence after surgical treatment and two recurrent patients also achieved CR without recurrence after RTR combined with PEB or PVB chemotherapy.
Box plots were also performed on plasma levels in MA.14 for patients at baseline; non-recurrent patients; and recurrent patients at baseline, prior to the recurrence period and in the recurrent period.
The recurrent patients in the model had either a local-regional recurrence or distant recurrence based on the proportion of the two types in the ATAC trial.
All recurrent patients, as well as those that survived without recurrence beyond 5 years, were included in this analysis.
However, analysed patients were selected from all recurrent patients, and no statement was made concerning locoregional recurrence among resected patients.
Thus, three studies concluded that resection for recurrence of BTC in selected patients (8.5 18 % of their recurrent patients) was feasible and offered survival benefits.
According to our findings, recurrent patients had significantly higher serum triglyceride level compared with no recurrent patients.
More than 40% of both newly diagnosed and recurrent patients achieved stable disease.
